ID   NCI-H2228-ARY
AC   CVCL_E6DB
SY   H2228-ARY
RX   PubMed=31900393;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_62268; Alectinib (CH5424802; RO5424802; AF-802).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E6A20 v3 fusion (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:9655; PTPN3; Name(s)=ALK-PTPN3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1543 ! NCI-H2228
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=31900393; DOI=10.1038/s41467-019-13771-5; PMCID=PMC6941996;
RA   Tsuji T., Ozasa H., Aoki W., Aburaya S., Yamamoto Funazo T., Furugaki K.,
RA   Yoshimura Y., Yamazoe M., Ajimizu H., Yasuda Y., Nomizo T., Yoshida H.,
RA   Sakamori Y., Wake H., Ueda M., Kim Y.H., Hirai T.;
RT   "YAP1 mediates survival of ALK-rearranged lung cancer cells treated
RT   with alectinib via pro-apoptotic protein regulation.";
RL   Nat. Commun. 11:74.1-74.16(2020).
//